









市场行情
/
股票
/
nasdaq-pepg
/

PepGen Inc

PEPG

5.308USD

-0.132-2.43%

交易中（美东）报价延迟15分钟

364.91M总市值

亏损市盈率 TTM



PepGen Inc

5.308

-0.132-2.43%

概览公司财务分析

概览

公司

财务

分析

关于 PepGen Inc 公司

PepGen Inc. is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies. The Company’s Enhanced Delivery Oligonucleotide (EDO) platform leverages cell-penetrating peptides to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake and nuclear delivery. Using these EDO peptides, the Company is generating a pipeline of oligonucleotide therapeutic candidates designed to target the root cause of serious diseases. It is focused on addressing the underlying cause of Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1), which have high unmet need. Its pipeline consists of two clinical stage programs, PGN-EDO51 for DMD patients who are amenable to an exon 51-skipping approach and PGN-EDODM1 for DM1 patients, and several additional preclinical stage programs. Its product candidates also include PGN-EDO53, PGN-EDO45 and PGN-EDO44.

PepGen Inc简介



公司代码PEPG

公司名称PepGen Inc

上市日期May 06, 2022

CEOMcArthur (James G)

员工数量81

证券类型Ordinary Share

年结日May 06

公司地址245 Main St, 2nd Floor

城市CAMBRIDGE

上市交易所NASDAQ OMX - NASDAQ BASIC

国家United States of America

邮编02142

电话17034568000

网址https://pepgen.com

公司代码PEPG

上市日期May 06, 2022

CEOMcArthur (James G)

PepGen Inc公司高管



名称

名称/职务

职务

持股

持股变动

Dr. James G. Mcarthur, Ph.D.

President, Chief Executive Officer, Director

53.19K

+3040.14%

Ms. Laurie Bartlett Keating, J.D.

Independent Chairman of the Board

4.17K

Ms. Mary Beth Delena, J.D.

General Counsel, Company Secretary

1.43K

-8.67%

Mr. Habib Joseph Dable

Independent Director

Ms. Heidi Henson, CPA

Independent Director

Dr. Paul D. Streck, M.D.

Executive Vice President, Head of Research & Development

Mr. Noel P. Donnelly

Chief Financial Officer

Dr. Joshua B. (Josh) Resnick, M.D.

Independent Director

Dr. Howard Mayer, M.D.

Independent Director

Dr. Kasra Kasraian, Ph.D.

Chief Technology Officer

名称

名称/职务

职务

持股

持股变动

Dr. James G. Mcarthur, Ph.D.

President, Chief Executive Officer, Director

53.19K

+3040.14%

Ms. Laurie Bartlett Keating, J.D.

Independent Chairman of the Board

4.17K

Ms. Mary Beth Delena, J.D.

General Counsel, Company Secretary

1.43K

-8.67%

Mr. Habib Joseph Dable

Independent Director

Ms. Heidi Henson, CPA

Independent Director

Dr. Paul D. Streck, M.D.

Executive Vice President, Head of Research & Development

收入明细

由于公司未披露，未能获取相关数据

由于公司未披露，未能获取相关数据

业务

地区

由于公司未披露，未能获取相关数据

股东统计

更新时间: 11月18日周二

持股股东

股东类型

持股股东

占比

RA Capital Management, LP

29.19%

Oxford Science Enterprises PLC

7.21%

Viking Global Investors LP

5.07%

Commodore Capital LP

3.43%

Vivo Capital, LLC

3.38%

其他

51.73%

持股股东

占比

RA Capital Management, LP

29.19%

Oxford Science Enterprises PLC

7.21%

Viking Global Investors LP

5.07%

Commodore Capital LP

3.43%

Vivo Capital, LLC

3.38%

其他

51.73%

股东类型

持股股东

占比

Venture Capital

40.87%

Hedge Fund

24.67%

Investment Advisor/Hedge Fund

14.63%

Investment Advisor

7.70%

Sovereign Wealth Fund

1.81%

Private Equity

1.21%

Research Firm

0.85%

Individual Investor

0.18%

其他

8.09%

机构持股



更新时间: 10月1日周三

报告期

机构数

持股数

持股占比

持股变动

2025Q3

157

41.73M

60.71%

+1.86M

2025Q2

165

31.28M

95.59%

-5.47M

2025Q1

168

31.44M

96.09%

-5.26M

2024Q4

160

31.09M

95.12%

-3.10M

2024Q3

156

31.41M

96.35%

-1.62M

2024Q2

150

31.22M

97.59%

-974.84K

2024Q1

140

30.76M

96.24%

+4.98M

2023Q4

127

22.26M

93.52%

+3.25M

2023Q3

124

22.70M

95.37%

+3.35M

2023Q2

119

23.17M

97.35%

+3.81M

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

RA Capital Management, LP

20.06M

29.19%

+9.38M

+87.70%

Sep 26, 2025

Oxford Science Enterprises PLC

4.96M

7.21%

+200.00K

+4.21%

Sep 30, 2025

Viking Global Investors LP

3.48M

5.07%

+2.00M

+134.91%

Sep 26, 2025

Point72 Asset Management, L.P.

2.76M

4.01%

+83.23K

+3.11%

Jun 30, 2025

Laurion Capital Management LP

810.76K

1.18%

Jun 30, 2025

The Vanguard Group, Inc.

937.02K

1.36%

+37.29K

+4.14%

Jun 30, 2025

持股ETF



更新时间: 12月6日周六

机构名称

占比

ProShares Ultra Nasdaq Biotechnology

0.03%

iShares Micro-Cap ETF

0.02%

Invesco Nasdaq Biotechnology ETF

0.02%

iShares Biotechnology ETF

0.01%

Proshares Ultra Russell 2000

Invesco Dorsey Wright SmallCap Momentum ETF

ProShares UltraPro Russell2000

ProShares Hedge Replication ETF

DFA Dimensional US Sustainability Core 1 ETF

Dimensional US Core Equity 1 ETF

ProShares Ultra Nasdaq Biotechnology

占比0.03%

iShares Micro-Cap ETF

占比0.02%

Invesco Nasdaq Biotechnology ETF

占比0.02%

iShares Biotechnology ETF

占比0.01%

Proshares Ultra Russell 2000

占比0%

Invesco Dorsey Wright SmallCap Momentum ETF

占比0%

ProShares UltraPro Russell2000

占比0%

ProShares Hedge Replication ETF

占比0%

DFA Dimensional US Sustainability Core 1 ETF

占比0%

Dimensional US Core Equity 1 ETF

占比0%

分红派息



近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股



公告日期

类型

比率

暂无数据

公告日期

类型

比率

暂无数据

常见问题

PepGen Inc的前五大股东是谁？



PepGen Inc 的前五大股东如下：
RA Capital Management, LP持有股份：20.06M，占总股份比例：29.19%。
Oxford Science Enterprises PLC持有股份：4.96M，占总股份比例：7.21%。
Viking Global Investors LP持有股份：3.48M，占总股份比例：5.07%。
Point72 Asset Management, L.P.持有股份：2.76M，占总股份比例：4.01%。
Laurion Capital Management LP持有股份：810.76K，占总股份比例：1.18%。